SUPPLEMENT
Q4 2022 — Earnings infographic
Q4 2022PDF · 1 pages4.2 MB
Joaquin Duato Chairman of the Board & Chief Executive Officer Johnson & Johnson “Our full year 2022 results reflect the continued strength and stability of our three business segments, despite macroeconomic challenges. I am inspired by our employees who make a difference in the health and lives of people around the world every day. As we look ahead to 2023, Johnson & Johnson is well-positioned to drive near-term growth, while also investing strategically to deliver long-term value.” For full financial data and non-GAAP reconciliations, please refer to Johnson & Johnson’s earnings release issued on January 24, 2023 available at http://www.investor.jnj.com/sales-earnings.cfm. *Non-GAAP financial measure; non-GAAP financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Non-GAAP measure; excludes the impact of translational currency. Certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes. Caution Concerning Forward-Looking Statements: This document contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding future operating and financial performance. You are cautioned not to rely on these forward-looking statements, which are based on current expectations of future events. For important information about the risks and uncertainties that could cause actual results to vary materially from the assumptions, expectations, and projections expressed in any forward-looking statements, review the “Note to Investors Concerning Forward- Looking Statements” included in the Johnson & Johnson earnings release issued on January 24, 2023 as well as the most recently filed Johnson & Johnson Reports on Forms 10-K and 10-Q. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments. Increased Decreased Full Year 2022 Results 2022 Sales Adjusted Diluted Earnings Per Share* $10.15 3.6% Diluted Earnings Per Share $6.73 (13.8)% Worldwide Increased $94.9B 6.2%* 1.3% Worldwide Increased Excluding acquisitions/ divestitures on an operational basis Note: values may have been rounded; the MedTech segment was previously referred to as the Medical Devices segment. $27.4MedTech worldwide reported sales increased 1.4% or 6.2% operationally. Primary operational drivers: Worldwide MedTech Sales Billion Billion $52.6 Worldwide Pharmaceutical Sales²Pharmaceutical worldwide reported sales increased 1.7% or 6.7% operationally. Primary operational drivers: Consumer Health worldwide reported sales decreased (0.5)%, but increased 3.6% operationally. Primary operational drivers: $15.0 Worldwide Consumer Health Sales² Billion Wound Closure Electrophysiology Contact Lens Hips Trauma Endocutters Biosurgery Knees Energy Surgical Vision -- 1 of 1 --